Core Insights - Catheter Precision, Inc. is participating in the 46th annual Heart Rhythm Society (HRS) meeting from April 24 to 27, 2025, in San Diego, California, showcasing its advancements in cardiac electrophysiology [1][2] Company Overview - Catheter Precision is a U.S.-based medical device company focused on developing innovative solutions for the treatment of cardiac arrhythmias, particularly in electrophysiology procedures [8] Product Highlights - The company will feature four abstracts at HRS 2025, including three for its VIVO system and one for the LockeT device, indicating strong research validation and product resonance with the electrophysiology community [3][4] - VIVO is a non-invasive 3D imaging system that aids in identifying the origin of ventricular arrhythmias, streamlining workflow and reducing procedure time, and has received FDA marketing clearance and CE mark [6] - LockeT is a suture retention device designed for wound closure after percutaneous venous punctures, classified as a Class 1 device registered with the FDA [5] Research Findings - A multi-center study in Europe demonstrated that VIVO achieved over 94% accuracy in pre-procedure localization, with long-term procedural success exceeding 83% [7] - VIVO's efficacy in mapping and ablation for difficult-to-map premature ventricular contractions (PVCs) was highlighted in studies from two centers [7] - The safety and effectiveness of LockeT were confirmed in a study involving 139 patients, particularly for large-bore access electrophysiological procedures [7] - A novel study showed VIVO's accuracy in predicting exit site locations for scar-dependent ventricular tachycardia (VT), with an 89% prediction rate and an 86% correlation with successful ablation sites [7]
Catheter Precision to Attend and Participate in the 46th Heart Rhythm Society